Proteomics International Laboratories (PIQ.AX) Stock Price

Proteomics International Laboratories Price

ASX·CLOSED
0.17AUD-0.0050 (-2.99 %)
Market closed

Revenue has compounded at 14.2% per year over the past 13 years to 3.31 M AUD. Proteomics International Laboratories's net margin stands at -245.0%, down from -195.1% several years earlier. Analysts set a median price target of 0.44 AUD, implying 165.8% above the current price. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 65% above its 52-week low.

Proteomics International Laboratories stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Proteomics International Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Proteomics International Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Proteomics International Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Proteomics International Laboratories Stock Price History
DateProteomics International Laboratories Price
8/21/20260.17 AUD
8/20/20260.17 AUD
8/19/20260.16 AUD
8/18/20260.16 AUD
8/17/20260.17 AUD
8/14/20260.16 AUD
8/13/20260.17 AUD
8/12/20260.16 AUD
8/11/20260.15 AUD
8/10/20260.16 AUD
8/7/20260.16 AUD
8/6/20260.17 AUD
8/5/20260.16 AUD
8/4/20260.14 AUD
8/3/20260.14 AUD
7/31/20260.14 AUD
7/30/20260.14 AUD
7/29/20260.15 AUD
7/28/20260.16 AUD
7/27/20260.16 AUD
7/24/20260.16 AUD
7/23/20260.17 AUD
7/22/20260.19 AUD
7/21/20260.15 AUD
7/20/20260.17 AUD
7/17/20260.17 AUD
7/16/20260.19 AUD
7/15/20260.19 AUD
7/14/20260.19 AUD
7/13/20260.19 AUD
7/10/20260.20 AUD
7/9/20260.17 AUD
7/8/20260.16 AUD
7/7/20260.16 AUD
7/6/20260.17 AUD
7/3/20260.20 AUD
7/2/20260.16 AUD
7/1/20260.14 AUD
6/30/20260.12 AUD
6/29/20260.11 AUD
6/26/20260.11 AUD
6/25/20260.10 AUD
6/24/20260.10 AUD
6/23/20260.11 AUD
6/22/20260.12 AUD
6/19/20260.12 AUD
6/18/20260.12 AUD
6/17/20260.13 AUD
6/16/20260.12 AUD
6/15/20260.12 AUD
6/12/20260.13 AUD
6/11/20260.13 AUD
6/10/20260.12 AUD
6/9/20260.13 AUD
6/5/20260.14 AUD
6/4/20260.14 AUD
6/3/20260.14 AUD
6/2/20260.14 AUD
6/1/20260.14 AUD
5/29/20260.14 AUD
5/28/20260.14 AUD
5/27/20260.14 AUD
5/26/20260.15 AUD
5/25/20260.15 AUD
5/22/20260.14 AUD
5/21/20260.14 AUD
5/20/20260.14 AUD
5/19/20260.16 AUD
5/18/20260.15 AUD
5/15/20260.15 AUD
5/14/20260.15 AUD
5/13/20260.14 AUD
5/12/20260.14 AUD
5/11/20260.15 AUD
5/8/20260.17 AUD
5/7/20260.19 AUD
5/6/20260.25 AUD
5/5/20260.24 AUD
5/4/20260.25 AUD
5/1/20260.25 AUD
4/30/20260.23 AUD
4/29/20260.23 AUD
4/28/20260.22 AUD
4/27/20260.26 AUD
4/24/20260.28 AUD
4/23/20260.26 AUD
4/22/20260.28 AUD
4/21/20260.28 AUD
4/20/20260.28 AUD
4/17/20260.28 AUD
4/16/20260.25 AUD
4/15/20260.25 AUD
4/14/20260.21 AUD
4/13/20260.21 AUD
4/10/20260.22 AUD
4/9/20260.22 AUD
4/8/20260.24 AUD
4/7/20260.25 AUD
4/2/20260.23 AUD
4/1/20260.29 AUD
3/31/20260.26 AUD
3/30/20260.28 AUD
3/27/20260.29 AUD
3/26/20260.29 AUD
3/25/20260.29 AUD
3/24/20260.30 AUD
3/23/20260.29 AUD
3/20/20260.30 AUD
3/19/20260.29 AUD
3/18/20260.31 AUD
3/17/20260.32 AUD
3/16/20260.33 AUD
3/13/20260.32 AUD
3/12/20260.34 AUD
3/11/20260.34 AUD
3/10/20260.34 AUD
3/9/20260.32 AUD
3/6/20260.32 AUD
3/5/20260.33 AUD
3/4/20260.31 AUD
3/3/20260.32 AUD
3/2/20260.31 AUD
2/27/20260.34 AUD
2/26/20260.33 AUD
2/25/20260.34 AUD
2/24/20260.35 AUD
2/23/20260.37 AUD
2/20/20260.38 AUD
2/19/20260.38 AUD
2/18/20260.38 AUD
2/17/20260.40 AUD
2/16/20260.40 AUD
2/13/20260.40 AUD
2/12/20260.40 AUD
2/11/20260.44 AUD
2/10/20260.46 AUD
2/9/20260.47 AUD
2/6/20260.45 AUD
2/5/20260.46 AUD
2/4/20260.49 AUD
2/3/20260.50 AUD
2/2/20260.50 AUD
1/30/20260.47 AUD
1/29/20260.57 AUD
1/28/20260.61 AUD
1/27/20260.65 AUD
1/23/20260.73 AUD
1/22/20260.73 AUD
1/21/20260.72 AUD
1/20/20260.73 AUD
1/19/20260.77 AUD
1/16/20260.80 AUD
1/15/20260.77 AUD
1/14/20260.84 AUD
1/13/20260.79 AUD
1/12/20260.67 AUD
1/9/20260.67 AUD
1/8/20260.69 AUD
1/7/20260.64 AUD
1/6/20260.65 AUD
1/5/20260.63 AUD
1/2/20260.72 AUD
12/31/20250.65 AUD
12/30/20250.67 AUD
12/29/20250.61 AUD
12/24/20250.53 AUD
12/23/20250.52 AUD
12/22/20250.54 AUD
12/19/20250.51 AUD
12/18/20250.55 AUD
12/17/20250.54 AUD
12/16/20250.53 AUD
12/15/20250.48 AUD
12/12/20250.49 AUD
12/11/20250.46 AUD
12/10/20250.41 AUD
12/9/20250.41 AUD
12/8/20250.43 AUD
12/5/20250.43 AUD
12/4/20250.42 AUD
12/3/20250.46 AUD
12/2/20250.49 AUD
12/1/20250.40 AUD
11/28/20250.41 AUD
11/27/20250.41 AUD
11/26/20250.39 AUD
11/25/20250.34 AUD
11/24/20250.34 AUD
11/21/20250.32 AUD
11/20/20250.32 AUD
11/19/20250.32 AUD
11/18/20250.31 AUD
11/17/20250.33 AUD
11/14/20250.34 AUD
11/13/20250.34 AUD
11/12/20250.35 AUD
11/11/20250.34 AUD
11/10/20250.34 AUD
11/7/20250.35 AUD
11/6/20250.34 AUD
11/5/20250.32 AUD
11/4/20250.32 AUD
11/3/20250.32 AUD
10/31/20250.34 AUD
10/30/20250.34 AUD
10/29/20250.34 AUD
10/28/20250.34 AUD
10/27/20250.34 AUD
10/24/20250.35 AUD
10/23/20250.35 AUD
10/22/20250.35 AUD
10/21/20250.35 AUD
10/20/20250.37 AUD
10/17/20250.38 AUD
10/16/20250.41 AUD
10/15/20250.38 AUD
10/14/20250.39 AUD
10/13/20250.37 AUD
10/10/20250.38 AUD
10/9/20250.38 AUD
10/8/20250.38 AUD
10/7/20250.41 AUD
10/6/20250.39 AUD
10/3/20250.37 AUD
10/2/20250.37 AUD
10/1/20250.34 AUD
9/30/20250.35 AUD
9/29/20250.37 AUD
9/26/20250.35 AUD
9/25/20250.32 AUD
9/24/20250.32 AUD
9/23/20250.32 AUD
9/22/20250.35 AUD
9/19/20250.35 AUD
9/18/20250.34 AUD
9/17/20250.29 AUD
9/16/20250.29 AUD
9/15/20250.30 AUD
9/12/20250.31 AUD
9/11/20250.31 AUD
9/10/20250.32 AUD
9/9/20250.32 AUD
9/8/20250.32 AUD
9/5/20250.31 AUD
9/4/20250.30 AUD
9/3/20250.30 AUD
9/2/20250.30 AUD
9/1/20250.31 AUD
8/29/20250.31 AUD
8/28/20250.32 AUD
8/27/20250.32 AUD
8/26/20250.32 AUD
8/25/20250.31 AUD
Access this data via the Eulerpool API
Get Free API Key

Proteomics International Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.61 M AUD
-1.99 M AUD
-1.74 M AUD
Jan 1, 2021
1.47 M AUD
-3.07 M AUD
-2.86 M AUD
Jan 1, 2022
1.72 M AUD
-4.98 M AUD
-4.97 M AUD
Jan 1, 2023
3.17 M AUD
-6.37 M AUD
-6.18 M AUD
Jan 1, 2024
3.27 M AUD
-6.75 M AUD
-6.38 M AUD
Jan 1, 2025
3.31 M AUD
-8.27 M AUD
-8.11 M AUD
Jan 1, 2026 (e)
6.36 M AUD
-5.15 M AUD
-5.00 M AUD
Jan 1, 2027 (e)
9.80 M AUD
-2.73 M AUD
-1.67 M AUD

Proteomics International Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 23, 2026, 2:44 PM
 
REVENUEM AUD
REVENUE GROWTH%
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
––––––1.001.001.001.001.003.003.003.006.009.00
–––––––––––200.00––100.0050.00
––––-1.00–-1.00-1.00-1.00-3.00-4.00-6.00-6.00-8.00-5.00-2.00
––––––-100.00-100.00-100.00-300.00-400.00-200.00-200.00-266.67-83.33-22.22
–––-1.00-1.00–-1.00-2.00-1.00-2.00-4.00-6.00-6.00-8.00-5.00-1.00
–––––––100.00-50.00100.00100.0050.00–33.33-37.50-80.00
65.4865.4865.4826.3450.5955.0760.6980.3387.42101.70105.53116.45125.85134.26134.26134.26
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Proteomics International Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Proteomics International Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Proteomics International Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Proteomics International Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Proteomics International Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Proteomics International Laboratories stock margins

The Proteomics International Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Proteomics International Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Proteomics International Laboratories.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
0.00 %
-123.39 %
-108.26 %
Jan 1, 2021
0.00 %
-209.38 %
-195.15 %
Jan 1, 2022
0.00 %
-289.48 %
-289.28 %
Jan 1, 2023
0.00 %
-200.92 %
-194.69 %
Jan 1, 2024
0.00 %
-206.46 %
-195.07 %
Jan 1, 2025
0.00 %
-249.57 %
-244.98 %
Jan 1, 2026 (e)
0.00 %
-80.95 %
-78.66 %
Jan 1, 2027 (e)
0.00 %
-27.84 %
-17.03 %

Proteomics International Laboratories Stock Revenue, EBIT, Earnings per Share

The Proteomics International Laboratories earnings per share therefore indicates how much revenue Proteomics International Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.02 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2021
0.01 AUD
-0.03 AUD
-0.03 AUD
Jan 1, 2022
0.02 AUD
-0.05 AUD
-0.05 AUD
Jan 1, 2023
0.03 AUD
-0.05 AUD
-0.05 AUD
Jan 1, 2024
0.03 AUD
-0.05 AUD
-0.05 AUD
Jan 1, 2025
0.02 AUD
-0.06 AUD
-0.06 AUD
Jan 1, 2026 (e)
0.04 AUD
-0.04 AUD
-0.03 AUD
Jan 1, 2027 (e)
0.06 AUD
-0.02 AUD
-0.01 AUD

Proteomics International Laboratories business model & stock analysis

Proteomics International Laboratories Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Proteomics International Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

Proteomics International Laboratories annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Proteomics International Laboratories shares outstanding

The number of shares of Proteomics International Laboratories was 134.26 M in 2025. This indicates how many shares Proteomics International Laboratories is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
87.42 M Stocks
Jan 1, 2021
101.70 M Stocks
Jan 1, 2022
105.53 M Stocks
Jan 1, 2023
116.45 M Stocks
Jan 1, 2024
125.85 M Stocks
Jan 1, 2025
134.26 M Stocks
Jan 1, 2026 (e)
134.26 M Stocks
Jan 1, 2027 (e)
134.26 M Stocks

Current Proteomics International Laboratories forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
42.86 % (3)
Sell
57.14 % (4)
12M Price Target
0.44
Last Price
0.17
Currency
AUD
12M Return Potential
165.82 %
LTM Return
0 %

Proteomics International Laboratories shareholder structure

% Name
10.38071%
Lipscombe (Richard John)
Lipscombe (Richard John)
0.70931%
House (Paul Edward)
House (Paul Edward)
0.41586%
MLC Asset Management
MLC Asset Management
0.12031%
Gardiner (Neville)
Gardiner (Neville)
0.09044%
MLC Investments Limited
MLC Investments Limited
0.08181%
Brinkworth (Aaron)
Brinkworth (Aaron)

Proteomics International Laboratories Executives and Management Board

14 members · 21 % women

VM

Mr. Vikesh Malik

Chief Commercialisation Officer

393,079.00 AUD

Management

RL

Dr. Richard Lipscombe

Managing Director, Executive Director

330,000.00 AUD
JG

Ms. Jacqueline Gray

Chief Financial Officer

288,189.00 AUD
SB

Dr. Scott Bringans

Head - Research

–
JK

Dr. Javed Khan

Business Manager - Analytical Services

–
CM

Mr. Chuck Morrison

Head - Business Development

–
KP

Dr. Kirsten Peters

Head - Clinical Studies

–

Board of Directors

NG

Mr. Neville Gardiner

Non-Executive Independent Director

175,954.00 AUD
PH

Mr. Paul House

Non-Executive Independent Director

48,125.00 AUD
JW

Dr. James Williams

Non-Executive Independent Chairman of the Board

–
AB

Mr. Aaron Brinkworth

Non-Executive Independent Director

–

Frequently asked questions about Proteomics International Laboratories

Analysts currently set an average price target of 0.44 AUD for the Proteomics International Laboratories stock (median: 0.44 AUD), implying +165.8 % versus the latest price. The consensus is based on 7 analyst ratings.

Proteomics International Laboratories Analyst Price Targets 2026

7 analysts currently rate the Proteomics International Laboratories stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Proteomics International Laboratories to generate revenue of 6.36 M AUD and earnings per share of -0.04 AUD.

Proteomics International Laboratories Analyst Price Targets 2026

Converted at the current exchange rate, the Proteomics International Laboratories share trades at 0.10 EUR (0.17 AUD).

The Proteomics International Laboratories share (PIQ.AX) is listed on 1 stock exchanges, including: ASX (PIQ.AX).

No history available for Proteomics International Laboratories.

The expected revenue of Proteomics International Laboratories is 6.36 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Proteomics International Laboratories is -5.00 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Proteomics International Laboratories is currently -4.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Proteomics International Laboratories stock.

The price-to-sales ratio (P/S) of Proteomics International Laboratories is currently 3.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Proteomics International Laboratories stock.

The Eulerpool Quality Score for Proteomics International Laboratories is 4/10.

The ISIN of Proteomics International Laboratories is AU000000PIQ0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Proteomics International Laboratories is PIQ.AX. The ticker symbol is used to trade Proteomics International Laboratories shares on the stock exchange.

Proteomics International Laboratories paid dividends every year for the past 0 years.

Proteomics International Laboratories is assigned to the 'Health' sector.

The dividends of Proteomics International Laboratories are distributed in AUD.

All fundamentals and in-depth analysis of Proteomics International Laboratories

Our stock analysis for Proteomics International Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Proteomics International Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Proteomics International Laboratories Stock
Proteomics International Laboratories Revenue→
Proteomics International Laboratories Stock
Proteomics International Laboratories Net Income→
Proteomics International Laboratories Stock
Proteomics International Laboratories P/E→
Proteomics International Laboratories Stock
Proteomics International Laboratories P/S→
Proteomics International Laboratories Stock
Proteomics International Laboratories EBIT→
Proteomics International Laboratories Stock
Proteomics International Laboratories Dividend→
Proteomics International Laboratories Stock
Proteomics International Laboratories Directors Dealings→
Proteomics International Laboratories Stock
Proteomics International Laboratories Stocks→
Proteomics International Laboratories Stock
Proteomics International Laboratories Market capitalization→
Proteomics International Laboratories Stock
Proteomics International Laboratories Debt→
Proteomics International Laboratories Stock
Proteomics International Laboratories Liabilities→
Proteomics International Laboratories Stock
Proteomics International Laboratories Equity→
Proteomics International Laboratories Stock
Proteomics International Laboratories AAQS→
Proteomics International Laboratories Stock
Proteomics International Laboratories Employees→
Proteomics International Laboratories Stock
Proteomics International Laboratories ROE→
Proteomics International Laboratories Stock
Proteomics International Laboratories ROA→
Proteomics International Laboratories Stock
Proteomics International Laboratories ROCE→
Proteomics International Laboratories Stock
Proteomics International Laboratories News→
Proteomics International Laboratories Stock
Proteomics International Laboratories Analyst Price Targets→

Health Stocks

Protext MobilityProteome SciencesProthena CorporationProteina CoProtoKinetixProtect Pharmaceutical CorporationProvectus BiopharmaceuticalsProtara TherapeuticsPsychemedicsProtalix BiotherapeuticsPT UBC Medical Indonesia TbkProtagonist TherapeuticsAll Stocks A–Z →